UNSPSC 51293604: Azepindole

This classification denotes an antidepressant agent with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BB6FW9T8J, chemically known as 2,3,4,5-tetrahydro-1h-(1,4)diazepino(1,2-a)indol but generally known as azepindole, which bears US NIH Compound Identifier 33471. European Medicines Agency schedules Azepindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05652MIG.

UNSPSC 51293604 Azepindole, a Commodity code, nominally addresses a single active pharmaceutical ingredient, but recent state and local opportunities tagged under this code reflect broader pharmaceutical procurement activity spanning naloxone, generic multi-source medications, and over-the-counter products distributed through established supply chains and direct-to-manufacturer models. State and local issuing bodies pursuing procurement under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida and the Texas Health and Human Services Commission represent the types of health-focused public bodies sourcing pharmaceutical products, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) exemplifies the regional cooperative model used by state and local entities to consolidate purchasing power and negotiate standardized pricing with manufacturers and wholesalers.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County released an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2026; the contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance, workers' compensation insurance, and commercial general liability coverage. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) posted April 3, 2026, to gather vendor capability data on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by Minnesota's Department of Administration, released an RFP (Solicitation Number S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) serving participating state and local facilities, including Oregon; the RFP emphasizes price competitiveness (75 percent evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and maintains performance penalties ranging from $200 to $1,500 per violation.